ReportWire

Tag: COVID-19 vaccine

  • China’s COVID case “explosion” not due to relaxed rules, WHO says, as 1st deaths reported since easing

    China’s COVID case “explosion” not due to relaxed rules, WHO says, as 1st deaths reported since easing

    [ad_1]

    China is facing its biggest public health challenge since the start of the coronavirus pandemic more than three years ago. Nine days after the government abruptly abandoned its draconian “zero-COVID” policy, halting mandatory mass-testing and forcible quarantines, COVID-19 is once again spreading like wildfire across the vast country.

    On Friday, local media outlets within China‘s tightly controlled press reported some of the first fatalities blamed on COVID since the restrictions were lifted. Two former Chinese state media journalists died in Beijing, on December 8 and 15, according to the outlets. Both were men in their 70s. Official government agencies have not yet confirmed the deaths were due to COVID — no coronavirus fatalities have been officially reported since the controversial zero-COVID policy was lifted. 

    But the World Health Organization says the strict policy of the last three years had stopped working anyway.

    “The explosion of cases in China is not due to the lifting of COVID restrictions,” said the WHO’s head of emergency programs, Dr. Mike Ryan. “The explosion of cases in China had started long before any easing of the zero-COVID policy.”

    If so, no one had told the Chinese public. 

    CHINA-HEALTH-VIRUS
    People line up outside a fever clinic in Beijing, China, to seek testing and treatment amid the ongoing COVID-19 pandemic, December 14, 2022.

    YUXUAN ZHANG/AFPTV/AFP/Getty


    The sudden U-turn by the ruling Communist Party just over a week ago hurled Beijing into chaos, with people unsure what the new rules were, or why they had been changed so dramatically. At “fever clinics” across the capital, people feeling under the weather have waited and worried for hours to be tested for the virus and get treatment for whatever is ailing them.

    For three years, Chinese officials had drilled the message into people’s minds that COVID-19 was a killer. As of nine days ago, the official message suddenly changed, telling people that, unless they’re really sick, they should just stay at home and get better.

    Virus Outbreak China
    Medical workers vaccinate a man against COVID-19 at a vaccination center in Beijing, December 16, 2022. 

    Ng Han Guan/AP


    The about-face in policy and rhetoric has been reinforced by upbeat state messaging, urging people to just get back to normal.

    But Beijingers still aren’t buying it. The still-empty streets and businesses of the capital show they’re opting for extreme caution.

    “I have to be more careful now,” said Liu, a 26-year-old Beijinger who works in e-commerce. “Because no one else is going to protect me.”

    CHINA-BEIJING-SUN CHUNLAN-INSPECTION (CN)
    Chinese Vice Premier Sun Chunlan inspects the Capital Institute of Pediatrics in Beijing, China, December 13, 2022, amid the ongoing COVID-19 pandemic. 

    Yan Yan/Xinhua/Getty


    On a visit to a Beijing hospital, China’s COVID-19 czar Sun Chunlan said the priority now was treatment, not case prevention and elimination. As part of the sweeping changes, the government admitted that it had stopped counting cases and promised a new focus on vaccinating the vulnerable. Many elderly Chinese remain un- or undervaccinated.

    Rare protests that erupted across China at the end of November, demanding an end to the rolling lockdowns and other restrictions of the zero-COVID policy, may have nudged the state away from the control measures. But grim economic data — and quite possibly knowledge of a looming infection tsunami — may have been clinchers in Beijing’s decision to pull the 180-degree turn.


    Global supply chain may benefit as China relaxes its “zero COVID” policies

    03:46

    And this surge is just getting started.

    A study partly funded by the Chinese Center for Disease Control and Prevention has warned the country urgently needs to roll out vaccinations and anti-viral drugs if it’s going to avoid 1 million COVID deaths over the coming weeks and months.

    [ad_2]

    Source link

  • Bill Clinton has COVID, but says he’s “doing fine overall” thanks to vaccines

    Bill Clinton has COVID, but says he’s “doing fine overall” thanks to vaccines

    [ad_1]

    The Temple Emanu-El Streicker Center Presents: Two Presidents, One Extraordinary Evening
    Former President Bill Clinton participates in The Temple Emanu-El Streicker Center Presents: Two Presidents, One Extraordinary Evening at Temple Emanu-El on November 10, 2022 in New York City.

    Michael Kovac/Getty


    Washington — Former President Bill Clinton said Wednesday that he had tested positive for COVID-19 but that his symptoms were mild and he encouraged people to get vaccinated. It is the latest health scare for the 76-year-old, who was briefly hospitalized last year and has undergone several operations since 2004.

    “I’m doing fine overall and keeping myself busy at home. I’m grateful to be vaccinated and boosted, which has kept my case mild, and I urge everyone to do the same, especially as we move into the winter months,” Clinton wrote on Twitter.


    White House officials urge Americans to get the COVID-19 booster shot

    03:36

    In October 2021 Clinton spent five nights in a hospital in California for a blood infection, before walking out arm in arm with his wife, former secretary of state Hillary Clinton.

    In 2004, at age 58, he underwent a quadruple bypass operation after doctors found signs of extensive heart disease.

    Six years later he had stents implanted in his coronary artery.

    This prompted him to adopt a vegetarian diet and to speak out publicly about how his change in food consumption helped him get healthier.

    “Maybe if I had… not eaten so many hamburgers and steaks, which I love, maybe if I had, you know, had slightly less stress in my life… maybe it would have been different,” Clinton told ABC News in 2004 after his successful heart surgery.

    Clinton led the United States for two presidential terms, from 1993-2001.


    Bill Clinton on Queen Elizabeth II

    04:38

    In the two decades since leaving the White House he has thrown himself into numerous humanitarian and diplomatic causes.

    He traveled the world, not just to receive generous speaking fees and to attend conferences but to visit disaster areas or raise funds for the fight against AIDS.

    Clinton, who once called himself “the comeback kid” during the 1992 Democratic Party primary battle, supported his wife’s unsuccessful presidential campaign against Donald Trump in 2016.

    Gradually his pace has slowed, and he has been traveling less in recent years.

    The Clintons now live in Chappaqua, New York.

    [ad_2]

    Source link

  • 58% of Americans dying due to COVID-19 were either vaccinated or boosted: Report

    58% of Americans dying due to COVID-19 were either vaccinated or boosted: Report

    [ad_1]

    In a shocker, around 58 per cent of Americans who succumbed to coronavirus in the month of August were either vaccinated or boosted. August was also the time when the BA.5 variant reached its peak. 

    During this period, death rates among people aged 6 months and above stood around six times higher than the rate of those who received their primary shots. Unvaccinated people over five years of age were at about 8 times the risk of dying from COVID-19 than those who received boosters, according to an analysis by the Vice President of the non-profit Kaiser Family Foundation (KFF) Cynthia Cox for The Washington Post’s The Health 202. 

    As per this analysis, the gap between those who received additional boosters and unvaccinated people over 50 years of age is even more striking. It mentioned, “Unvaccinated people 50 and up had 12 times the risk of dying from COVID-19 than adults the same age with two or more booster doses.”

    This was around 35 per cent higher than the COVID-19 fatalities reported in September last year. As of September 2021, the vaccinated population made up 23 per cent of the COVID-19 deaths in the US whereas this number went up to 42 per cent in January and February this year. 

    These numbers make sense given that a large population of Americans has been inoculated with at least the primary doses of the vaccines, according to Cox. 

    Cox further explained that individuals belonging to high-risk groups such as the elderly are also more likely to be vaccinated. So, why do COVID-19 deaths in America account for a majority of the inoculated population? 

    Cox mentioned that vaccines tend to lose potency over time as more vaccine-resistant variants emerge. She further said that continued booster shots are key to keeping the death count low and that being unvaccinated is not an option. 

    Omicron subvariant – BA.5– became dominant in July this year and accounted for a majority of new COVID-19 deaths in the US. Going ahead, she stated, “We can no longer say this is a pandemic of the unvaccinated.”

    This data came out after Dr Anthony Fauci urged Americans to go out in large numbers and get booster doses against COVID-19. He said, “The final message I give you from this podium is that please, for your own safety, for that of your family, get your updated COVID-19 shot as soon as you’re eligible.”

    Representative Hank Johnson also asked Americans to not only get their updated COVID vaccine but also to remind their relatives to do the same. Johnson tweeted, “2 days out until Thanksgiving! When you call your relatives to get that last-minute recipe, remind them to get their updated COVID vaccine. Find free updated vaccines for everyone 5+ at vaccines.gov.”

    Also read: Bharat Biotech, Health Ministry rubbish claims that Covaxin was ‘rushed due to political pressure’

    [ad_2]

    Source link

  • Doctors urge COVID-19 and flu vaccines ahead of holidays, as flu cases surge

    Doctors urge COVID-19 and flu vaccines ahead of holidays, as flu cases surge

    [ad_1]

    As hospitals and emergency rooms fill up amid a surge of flu cases, doctors are warning people to get vaccinated for that and COVID-19, especially ahead of the holiday season. The flu is already hitting hard, with 22 states and Washington, D.C., reporting high levels of activity, according to the Centers for Disease Control and Prevention.

    The CDC also said the hospitalization rate for flu is at the highest for this early in the season in a decade.

    Dr. Daniel Guzman, of Cook Children’s Medical Center in Fort Worth, said the one-two punch of RSV — a respiratory illness common in children — and flu cases has filled up his emergency room. He added that the rate of cases in the hospital nearly doubled in the last week from 172 to almost 338 flu patients.

    It’s why doctors are urging people to get vaccinated. Andrew Talbot, a Massachusetts teacher, said he got his COVID-19 booster before he travels to see his immunocompromised mother for the holidays.

    “I’m aware of the fact that there is, you know, COVID that comes and goes in waves,” he told CBS News. “And especially with her being on immunosuppression drugs, I didn’t want to risk bringing anything home.”

    But, only 10% of people age 5 and older have received the updated COVID-19 vaccine and just 21% of adults say they’ve been vaccinated against the flu, according to the CDC.

    “You’re protecting your entire bubble of your family members,” Guzman said about getting vaccinated. “You know, those that are really old to those that are really young. And so it’s really important that we do as much as we can to help protect them.”

    To stay safe this holiday season, experts advise to get vaccinated, consider a “mini-quarantine” the week before traveling, testing before gathering and staying home if you feel sick.

    “Never too late to get a flu shot,” Guzman said. “I think we have to stress it’s an important thing to help protect yourself as well as everyone around you, that everyone goes out and get a flu shot.”

    [ad_2]

    Source link

  • China starts using a COVID-19 vaccine inhaled through the mouth

    China starts using a COVID-19 vaccine inhaled through the mouth

    [ad_1]

    The Chinese city of Shanghai started administering an inhalable COVID-19 vaccine on Wednesday in what appears to be a world first.

    The vaccine, a mist that is sucked in through the mouth, is being offered for free as a booster dose for previously vaccinated individuals, according to an announcement posted on an official city social media account.

    Needle-free vaccines may persuade people who don’t like getting a shot to get vaccinated, as well as help expand vaccination in poor countries because they’re easier to administer.

    China doesn’t have vaccine mandates but wants more people to get booster shots before it relaxes strict pandemic restrictions that are holding back the economy and increasingly out of synch with the rest of the world.

    A video posted by an online Chinese state media outlet showed people at a community health center sticking the short nozzle of a translucent white cup into their mouths. Accompanying text said that after slowly inhaling, one individual held his breath for five seconds, with the entire procedure completed in 20 seconds.

    “It was like drinking a cup of milk tea,” one Shanghai resident said in the video. “When I breathed it in, it tasted a bit sweet.”

    A vaccine taken in the mouth could also fend off the virus before it reaches the rest of the respiratory system, though that would depend in part on the size of the droplets, one expert said.

    Larger droplets would train defenses in parts of the mouth and throat, while smaller ones would travel further into the body, said Dr. Vineeta Bal, an immunologist in India.

    Chinese regulators approved the vaccine for use as a booster in September. It was developed by Chinese biopharmaceutical company Cansino Biologics Inc. as an aerosol version of the same company’s one-shot adenovirus vaccine, which uses a relatively harmless cold virus.

    Cansino has said the inhaled vaccine has completed clinical trials in China, Hungary, Pakistan, Malaysia, Argentina and Mexico.

    Regulators in India have approved a nasal vaccine, another needle-free approach, but it has yet to be rolled out. The vaccine, developed in the U.S. and licensed to Indian vaccine maker Bharat Biotech, is squirted in the nose.

    About a dozen nasal vaccines are being tested globally, according to the World Health Organization.

    [ad_2]

    Source link

  • Will the Bivalent Booster Cause Worse Side Effects?

    Will the Bivalent Booster Cause Worse Side Effects?

    [ad_1]

    For as long as my marriage lasts, my household will be divided by reactions to vaccines.

    I am, fortunately, speaking of physical reactions rather than ideological ones; my partner and I are both shot enthusiasts, a fact we verified on our first date. But if my immune system is a bashful wallflower, rarely triggering more than a sore arm in the hours after I get a vaccine, then my spouse’s is a party animal. Every immunization I’ve watched him receive—among them, four doses of Moderna’s COVID-19 vaccine—has absolutely clobbered him with fevers, chills, fatigue, and headaches for about a full day. When he got the flu shot and the bivalent COVID jab together a few weeks ago, he ended up taking his first day off work in more than a decade. As usual, the same injections caused me so few symptoms that I wondered if I was truly dead inside.

    “Why don’t you feel anything?” my spouse howled at me from the bedroom, where his sweat was soaking through the sheets. “Sorry,” I yelled back from the kitchen, where I was prepping four days’ worth of meals between work calls after returning from an eight-mile run.

    If this is how every autumn will go from now on, so be it: A few hours of discomfort is still worth the rev-up in defenses that vaccines offer against serious disease and death. But it’s not hard to see that gnarly side effects will only add to the many other factors that work against COVID-vaccine uptake, including lack of awareness, sloppy messaging, dwindling access, and spotty community outreach. Back in the spring, when I spoke with several people who hadn’t gotten boosters despite being eligible for many, many months, several of them cited the post-shot discomfort as a reason. Now I’m getting texts and calls from family members and friends—all up to date on their previous COVID vaccines—admitting they’ve been dillydallying on the bivalent to avoid those symptoms too. “I don’t know if we’re going to continue to get strong buy-in from the public if they have this sort of reaction every year,” says Cindy Leifer, an immunologist at Cornell University.

    The good news, at least, is that experts told me they don’t expect this bivalent recipe—or future autumn COVID shots, for that matter—to be worse, side-effect-wise, than the ones we’ve received before. It’ll take a while for data to confirm that, especially considering that more than a month into this fall’s rollout, fewer than 15 million Americans have received the updated shot. But Kathleen Neuzil, a vaccinologist at the University of Maryland School of Medicine who has studied the performance of COVID vaccines in clinical trials, pointed out to me that the mRNA shots’ ingredients have been swapped out before without altering the rate of side effects. As the alphabet soup of variants began to sweep the world in early 2021, she told me, vaccine makers started to tinker with alternate formulations, sometimes combining multiple versions of the spike protein into a single shot—“and they’re all comparable.” (If anything, early data suggest that bivalent shots containing an Omicron variant spike may be easier to take.) The same goes for flu vaccines, which are also retooled each year: When measured across the population, the frequency and intensity of side effects remain more or less the same.

    On average, then, mRNA-vaxxed people can probably expect to have an annual experience that’s pretty similar to the one they had with their first COVID booster. As studies have shown, that one was actually better for most people than dose No. 2, the most unpleasant of the injections so far. (The math, of course, becomes tougher for people getting another vaccine, such as the flu shot, at the same time.) There are probably two main reasons why side effects have lessened overall, experts told me. First, the spacing: Most people received the second dose in their Pfizer or Moderna primary series just three or four weeks after the first. That’s an efficient way to get a lot of people “fully vaccinated” in a short period of time, but it means that many of the immune system’s defensive cells and molecules will still be on high alert. The second shot could end up fanning a blaze of inflammation that was never quite put out. In line with that, researchers have found that spacing out the primary-series doses to eight weeks, 12 weeks, or even longer can prune some side effects.

    Dose matters a lot too: Vaccines are, in a way, stimulants meant to goad the immune system into reacting; bigger servings should induce bigger jolts. When vaccine makers were tinkering with their recipes in early trials, higher doses—including ones that were deemed too large for further testing—produced more side effects. Each injection in Moderna’s primary series contains more than three times the mRNA packaged into Pfizer’s, and Moderna has, on average, caused more intense side effects. But Moderna’s booster and bivalent doses contain a smaller scoop of the stimulating material: People 12 and older, for instance, get 50 micrograms instead of the 100 micrograms in each primary dose; kids 6 to 11 years old get 25 micrograms instead of 50. (All of Pfizer’s doses stay the same size across primaries and boosters, as long as people stay in the same age group.) People who switch between brands, then, may also notice a difference in symptoms.

    It’s a tricky balance, though. Sometimes, the immune system adjusts the magnitude of its protection to match the danger posed by a pathogen (or shot), a bit like titrating a crisis response to the severity of a threat—so it’s important that vaccine makers don’t undershoot. For better or worse, the mRNA-based COVID vaccines do seem to cause a rougher response than most other vaccines, including annual flu shots. One of the offending ingredients might be the mRNA itself, which codes for SARS-CoV-2’s spike protein. But Michela Locci, an immunologist at the University of Pennsylvania, told me that the mRNA’s packaging—a greasy fat bubble called a lipid nanoparticle—may be the more likely culprit. For some people, in any case, the side effects of COVID shots might be on par with those of the two-dose Shingrix vaccine, one of the most infamously reactogenic immunizations in our roster. Leifer, who has received both, told me the second dose of each “floored” her to about the same extent.

    The fact that I get fewer side effects than my spouse does not imply that I’m any less protected. A ton of factors—genetics, hormone levels, age, diet, sleep, stress, pain tolerance, and more—could potentially influence how someone experiences a shot. Women tend to have more reactive bodies, as do younger people. But there are exceptions to those trends: I’m one of them. The whole topic is understudied, Locci told me. Her own recent experience with the bivalent threw her for a loop. After her first, second, and third dose of Moderna each ratcheted up in side-effect severity, she cleared her calendar for the couple of days following her bivalent, “afraid I was going to be in bed with a fever again,” she said: “But it was a light headache for a morning, and then it was over.” She has no idea what next year will bring.

    Either way, side effects such as fevers and chills tend to be short-lived. “Very few side effects are severe,” Neuzil told me, “and COVID continues to be a severe disease.” Still, Grace Lee, a pediatrician at Stanford and the chair of the CDC’s Advisory Committee on Immunization Practices, hopes that scientists will keep developing new COVID vaccines that might come with fewer post-shot issues—including the very rare ones, such as myocarditis—without sacrificing immune protection. Lee doesn’t tend to react much to vaccines, but her daughter “always misses school the next day,” she told me. “I plan her shots for a Friday afternoon so she can lay out all Saturday.” Early on, when hardly anyone had immunity to the virus, signing everyone up for somewhat reactogenic shots was a no-brainer—especially given the hope that two doses would yield many, many years of protection. Now that we know it’s a repeated need, Neuzil said, “the equation changes a bit.”

    People aren’t totally helpless against side effects. Deepta Bhattacharya, an immunologist at the University of Arizona, had an “awful, terrible” experience with his second and third doses, which slammed him with 102- and 103-degree fevers, respectively. He weathered the side effects without intervention, worried that a painkiller would curb not just the agony, but also his protective immune response. This time, though, armed with new knowledge from his own lab that anti-inflammatory and pain-relieving drugs don’t blunt antibody levels, “the first sign I feel even the slightest bit shitty,” he told me, “I’m dosing up.”

    I’ll probably do the same for my spouse the next time he’s due for a vaccine of any kind … likely while I chill on the sidelines. Bhattacharya’s spouse, too, is kind of an immune introvert, a fact that he bemoans. “Her only side effect was she felt thirsty,” he said. “It’s just not fair.”

    [ad_2]

    Katherine J. Wu

    Source link

  • SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

    SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

    [ad_1]

    Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired.

    Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.

    “Since December 2021, we stopped the production (of Covishield). We had a stock of a few hundred million doses at that time and of that, 100 million doses have already expired,” said Poonawalla when asked about the update on the Covishield vaccine.

    He said the SII’s vaccines are allowed to be mixed.

    “Now, Covovax should be allowed in two weeks. So I think they will and should probably have the policy to mix boosters. If WHO allowed it, then maybe the Indian regulator will and should allow it. But again, boosters have no demand at the moment. There is lethargy generally. People are fed up of COVID, vaccines. To be honest, I am also fed up with it. We all are,” he said.

    Going forward, when people take a few shots every year, they may take anti-coronavirus vaccines and other shots together, Poonawalla said, adding, “It will become that kind of a product.”

    “In India, there is no culture of taking flu shots as we see it in the West. We tried when we launched a few vaccines in 2010. During the H1NI pandemic in 2011, no one took it. Flu is not something that sounds scary to people. They just do not want to take it,” he said.

    Covishield was produced at the SII’s Pune facility with a master seed from Oxford University and AstraZeneca. The SII had announced its partnership with Oxford University to manufacture the vaccine in April 2020.

    [ad_2]

    Source link

  • Why CDC advisers voted to add COVID vaccines to routine immunizations

    Why CDC advisers voted to add COVID vaccines to routine immunizations

    [ad_1]

    COVID vaccines should be part of the federal government’s list of routinely recommended vaccinations, a panel of Centers for Disease Control and Prevention experts said Thursday.

    The CDC’s Advisory Committee on Immunization Practices voted unanimously to back the move, amid a two-day long meeting.

    The move, part of a series of proposed changes to documents which are revised early every year, would amount to little more than summarizing recommendations already decided by the agency’s advisers, the CDC said.

    “It’s important to note that there are no changes in COVID-19 vaccine policy, and today’s action simply helps streamline clinical guidance for healthcare providers by including all currently licensed, authorized and routinely recommended vaccines in one document,” the CDC said in a statement published on Thursday.

    It also has responded to misleading claims aired by Fox News host Tucker Carlson and others, which falsely accused the CDC of moving to mandate COVID-19 vaccinations to enroll in public schools. 

    In the hotly contested Senate contest in Nevada, Republican candidate Adam Laxalt on Thursday called on his opponent – incumbent Democratic Senator Catherine Cortez Masto – to “say whether she stands by the actions taken by the CDC on forced vaccinations of children in Nevada or not.”

    “Indeed, there are vaccines that are on the schedule right now that are not required for school attendance in many jurisdictions, such as seasonal influenza. Local control matters, and we honor that,” Dr. Nirav Shah, Maine’s top health official and a member of the CDC’s Advisory Committee on Immunization Practices, said during the meeting ahead of the vote.

    While local authorities often look to the federal health agencies for guidance on the nation’s widely varying school immunization requirements, administration officials have repeatedly reiterated that they have no jurisdiction to impose such mandates in the classroom.

    “The decision around school entrance for vaccines rests where it did before, which is at the state level, the county level, and at the municipal level, if it exists at all,” Shah said.

    Shah and other members of the panel acknowledged the slew of online comments they had received ahead of the meeting over the topic, some pleading with them not to require COVID vaccinations in schools.

    After Thursday’s vote, the agency then will seek sign-off from a range of professional groups including the American Academy of Family Physicians and American Pharmacists Association. 

    The new schedules for children, adolescents and adults will then be published in February 2023 by the CDC.

    Outside of COVID-19 changes, other proposed changes presented to the group included incorporating the new pediatric recommendations voted on in June for pneumococcal conjugate vaccine and clarifying that Dengue vaccine should not be administered to children who are only visiting parts of the world where the disease is endemic.

    “This represents sort of a summary of existing recommendations. But I will acknowledge, I appreciate that there is a symbolism in adding COVID-19 to the childhood immunization schedule. And that symbolism is that we view this as routine, and that we view this as COVID is here to stay,” said Dr. Matthew Daley, a member of the panel.

    The vote comes a day after the panel also endorsed adding COVID-19 to the federally funded Vaccines for Children program, which covers routine immunizations for uninsured children.

    Under the Affordable Care Act, most private health insurance plans are required to cover vaccines included on the recommended immunization schedules at no cost.

    But while the cost of COVID-19 vaccines has been borne by the federal government for all Americans during the public health emergency, the Biden administration has said for months that it would need to begin preparing to transition the shots to a private market next year as funds run dry.

    “This is an access issue. This is an issue to allow children that don’t have insurance to gain access to this vaccine. It’s particularly important, as we move on to commercialization of the vaccine,” the CDC’s José Romero told the committee on Wednesday.

    CDC officials told the committee on Wednesday that their vote would allow the Vaccines for Children to begin contracting for doses to provide to doctors, once the supply of vials from the federal COVID-19 response runs out.

    The votes also do not impact the coverage by the Countermeasures Injury Compensation Program of the vaccines, which remain in part under emergency use authorizations.

    “It is not listing this as a routine vaccine for children to enter school. And it is not a change in our policy for these vaccines,” Romero said.

    [ad_2]

    Source link

  • WHO Director-General Says COVID Remains Emergency, Could Still Surprise Us

    WHO Director-General Says COVID Remains Emergency, Could Still Surprise Us

    [ad_1]

    The director-general of the World Health Organization on Wednesday said the coronavirus pandemic “remains a public health emergency of international concern.”

    Dr. Tedros Adhanom Ghebreyesus said the WHO’s Emergency Committee on COVID-19 came to that conclusion during a meeting last week, and he shares that view. The committee also called on countries to make testing, therapeutics and vaccines more widely available to at-risk communities.

    “While the global situation has obviously improved since the pandemic began, the virus continues to change, and there remain many risks and uncertainties,” the director-general said. “This pandemic has surprised us before and very well could again.”

    The WHO first announced COVID-19 constitutes an emergency in January 2020.

    Last week, the White House announced it was extending its own COVID-19 public health emergency declaration until January as the Biden administration braces for more cases of COVID-19 and flu this winter, defying Republicans who had been calling on the president to end it.

    The emergency declaration has, among other things, allowed the White House to distribute treatments and testing for free, and issue emergency authorization of COVID-19 vaccines, according to The Associated Press.

    U.S. House Minority Leader Kevin McCarthy (R-Calif.) recently told Punchbowl News his party does not plan to approve any additional COVID-19 funding, which President Joe Biden has requested for vaccines and tests.

    Meanwhile, the U.S. is seeing the emergence of new variants.

    For the week ending on Oct. 15, the Centers for Disease Control and Prevention reported BA.5 was still making up the majority of COVID-19 infections, but variants BQ.1.1 and BQ.1 collectively accounted for over 11% of cases.

    Dr. Anthony Fauci, Biden’s chief medical adviser, said the speed with which these two variants are spreading is worrying.

    “When you get variants like that, you look at what their rate of increase is as a relative proportion of the variants, and this has a pretty troublesome doubling time,” Fauci told CBS News.

    Dr. Ashish Jha, the White House COVID-19 response coordinator, has been calling on people to get their updated booster vaccine, which targets the original COVID-19 strain as well as the omicron variant and BA.5 subvariant.

    “Don’t wait. Get your new flu shot and get your new COVID shot today. If Americans did that, we could save hundreds of lives each day this winter,” Jha told White House reporters last week.

    But Americans have reportedly been slow to take it up. As of Oct. 12, only 14.7% of those eligible had been boosted with the new bivalent vaccine, according to the CDC.

    [ad_2]

    Source link

  • Hundreds of students at a San Diego high school call out amid flu outbreak

    Hundreds of students at a San Diego high school call out amid flu outbreak

    [ad_1]

    Data from the U.S. Centers for Disease Control and Prevention show that the flu season is off to an early start, with a rash of flu-like cases reported in Texas, parts of the southeast, New York City and Washington, D.C. One San Diego high school seemingly has a flu outbreak, causing 1,400 students to be absent.

    The outbreak at Patrick Henry High School started Monday, doubled on Wednesday, and now, more than half the student body is out sick.

    “There was a homecoming dance and game on the weekend prior to this Monday,” Dr. Howard Taras, a physician for the San Diego Unified School District, told CBS News. “You’d think that it would take several days for them to become infectious to others, but it didn’t.”

    The CDC said prior to the COVID-19 pandemic, there were 36 million cases of the flu in the U.S. With masking and social distancing, U.S. cases plummeted to just thousands — the lowest ever recorded.

    But now, most mandates are gone.

    “The last two years, people haven’t been exposed too much influenza, so their immunity to it may be down,” said CBS News chief medical correspondent Jonathan LaPook.

    The CDC said it’s safe to get the flu shot and COVID-19 booster together so that you can be prepared for what’s predicted to be a severe flu season.

    [ad_2]

    Source link

  • How much better are updated COVID boosters? Pfizer announces first results in human clinical trial

    How much better are updated COVID boosters? Pfizer announces first results in human clinical trial

    [ad_1]

    New human clinical trial data announced by Pfizer and its German partner BioNTech suggest the updated COVID-19 vaccine boosters introduced this fall will outperform their original formulation in guarding against the BA.4 and BA.5 variants, the companies said Thursday. 

    The new findings are the first from human trials examining the effectiveness of the “bivalent” booster shots, which blend a component targeting the original strain of the virus with another designed to protect against the Omicron BA.4 and BA.5 variants.

    The companies also found that the updated boosters with this Omicron component, which are otherwise virtually identical to the original formulations of the shot, appeared to be similarly well-tolerated and safe.

    “These early data suggest that our bivalent vaccine is anticipated to provide better protection against currently circulating variants than the original vaccine and potentially help to curb future surges in cases this winter,” Pfizer’s CEO Albert Bourla said in a release.

    Based on examining blood samples drawn from 80 people a week after getting the updated boosters, the companies say that recipients across the board saw “a substantial increase” in their neutralizing antibody response against the BA.4 and BA.5 variants.

    A comparison done in people older than 55 years old found the antibody response from the original shots was “more limited” against these variants, compared to those who got the updated boosters.

    Further analyses, including a comparison from younger adults, is still ongoing.

    “These are the first data coming out of the trial and currently only a comparison in the above 55 age group was completed to the original vaccine. We don’t have data yet on the 18-55 year old adults,” BioNTech spokesperson Alexander Siebert said.

    A spokesperson for Moderna did not respond to a request for comment about the timeline for data from their updated boosters, which are also being studied in humans.

    Data from studies in mice

    The Food and Drug Administration and the Centers for Disease Control and Prevention had greenlighted an update to the boosters back in September in hopes of getting ahead of a widely-anticipated fall and winter wave of the virus.

    Data reviewed by the CDC’s outside advisers and the FDA found other formulations changed to target previous strains, like the BA.1 variant of Omicron, that were tested in the past by Moderna and Pfizer-BioNTech in humans, appeared safe and effective.

    An ongoing nonclinical study by Pfizer in mice that were given the updated boosters suggested the new shots would perform similarly well to those other versions, providing at least “incremental benefit.” Moderna later released results from their study in mice of the updated boosters.

    Both the agencies and their outside advisers acknowledged key unanswered questions at the time, including on exactly how much additional protection would be offered by the updated boosters.

    More human clinical trial data would also be needed before the shots for the primary series vaccinations could be switched over, the FDA concluded. The regulator may convene its own panel of vaccine advisers later this year on this topic, officials said.

    Some of the CDC’s advisers also expressed reservations over clearing the updated boosters without clinical data in humans, despite the other promising data.

    But both the FDA and a majority of the CDC’s advisers ultimately decided that the benefits outweighed the risks of rolling out the shots at the time, instead of waiting months for clinical trials to be completed. 

    “We’re pretty confident that what we have is very similar to the situation that we’ve done in the past with influenza strain changes, where we don’t do clinical studies for them in the United States. We know from the way the vaccine works and from the data that we have that we can predict how well the vaccine will be working,” the FDA’s Peter Marks told reporters in August.

    [ad_2]

    Source link

  • FDA and CDC clear updated COVID boosters for kids as young as 5 years old

    FDA and CDC clear updated COVID boosters for kids as young as 5 years old

    [ad_1]

    The Food and Drug Administration announced Wednesday that it had granted emergency use authorization for updated COVID-19 vaccine boosters for Americans as young as 5 years old, and the Centers for Disease Control and Prevention officially signed off on their use. The boosters can be given at least two months after their previous shot of the vaccine.

    “FDA’s authorization of updated (bivalent) COVID-19 vaccines for this younger age group, and CDC’s recommendation for use, are critical next steps forward in our country’s vaccination program—a program that has helped provide increased protection against severe COVID-19 disease and death,” CDC Director Dr. Rochelle Walensky said in a statement. 

    “Since children have gone back to school in person and people are resuming pre-pandemic behaviors and activities, there is the potential for increased risk of exposure to the virus that causes COVID-19,” Dr. Peter Marks, the FDA’s top vaccines official, said in a statement.

    The FDA said it had considered data on the immune response and safety from the shots in children who had gotten a booster of the previous formulation to make its decision.

    These new bivalent shots are manufactured in a nearly identical process from Pfizer-BioNTech and Moderna, aside from adding in a component designed to target the BA.4 and BA.5 variants.

    “As families across the country take part in fall festivities and plan for the upcoming holiday season, we aim to provide school-aged children with additional protection against the Omicron BA.4/BA.5 subvariants, which continue to account for more than 80% of cases in the U.S.,” Pfizer’s CEO Albert Bourla said in a statement.

    Pre-ordering wrapped up last week for the new vaccines from Pfizer and BioNTech formulated for this younger age group. A spokesperson for Pfizer said they have the ability to ship up to 6 million doses for younger children within the coming week, following their final quality-control checks.

    A spokesperson for the Department of Health and Human Services did not respond to a request for comment on how many shots were requested of the new Pfizer vaccines for younger ages.

    Moderna’s booster for kids is simply a smaller dose of the same formulation that is already being distributed for older age groups, and did not need to be pre-ordered.

    Compared to adults, a smaller share of children will be eligible to get the updated booster, because fewer have gotten the vaccine to begin with.

    Only around 60.8% of adolescents 12 and older and 31.5% of children 5 and older have so far received even their first two COVID vaccine doses, according to CDC data.

    Marks acknowledged that the virus “tends to be less severe in children than adults,” but warned that kids still faced a risk of hospitalization or long-term effects from the virus and would benefit from the shots.

    The CDC recently estimated that some 86.3% of children in the U.S. have survived at least one COVID-19 infection, based on surveying for antibodies in blood samples.

    “We encourage parents to consider primary vaccination for children and follow-up with an updated booster dose when eligible,” said Marks.

    Wednesday’s decision leaves only children under 5 years old ineligible to receive the updated COVID booster.

    Federal health officials have previously said they expected these shots could be made available for the next youngest age group, down to 6 months old, by the winter.

    Moderna said Wednesday in a release that it expected to complete its application for emergency use authorization in this youngest age group “later this year.”

    [ad_2]

    Source link

  • Are We Really Getting COVID Boosters Every Year Forever?

    Are We Really Getting COVID Boosters Every Year Forever?

    [ad_1]

    School is in session, pumpkin spice is in season, and Americans are heading to pharmacies for what may soon become another autumn standby: your annual COVID shot. On Tuesday, the White House announced the start of a “new phase” of the pandemic response, one in which “most Americans” will receive a COVID-19 vaccine just “once a year, each fall.” In other words, your pandemic booster is about to become as routine as your physical exam or—more to the point—your flu shot. One more health-related task has been added to your calendar, and it’s likely to remain there for the rest of your life.

    From a certain standpoint, this regimen makes a lot of sense. The pandemic’s biggest surges so far have come in the winter, and a fall booster could go a long way toward mitigating the next of those surges. What’s more, the new plan greatly simplifies COVID-vaccination regimens, both for the public and for providers. “It has been bewildering in many cases to understand who is eligible for a booster, how many boosters, when, which boosters, how far apart,” Jason Schwartz, a vaccine-policy expert at Yale, told me. “I think that has held down booster uptake in some really discouraging ways.” In a sense, White House COVID-19 Response Coordinator Ashish Jha told me, the new plan just codifies the way things already worked: The last time low-risk Americans became eligible for another shot was last fall. (The elderly and immunocompromised have operated on a different schedule and will likely continue to do so, Jha said.)

    Still, some public-health experts worry that the White House is jumping the gun. Back in April, a number of them told Stat News’s Helen Branswell they were concerned that the U.S. would adopt such a policy without the data needed to support it. When the White House made its announcement on Tuesday, many felt their concerns had been vindicated. “We’ve had twists and turns and surprises every single step of the way with COVID, and the idea that we’re going to have one shot and then we’re done is not really consistent with how things have worked in the past,” Walid Gellad, a professor at the University of Pittsburgh School of Medicine, told me. The plan, in his view, glosses over considerable uncertainties.

    For one thing, it assumes that the virus will follow an annual schedule with peaks in the fall and winter—not unlikely, but also not a given. For another, we still don’t have a firm grasp on the magnitude or duration of the benefits offered by the new Omicron-specific vaccine. For all we know, Gellad told me, the added protection afforded to someone who gets the shot tomorrow may have largely dissipated by New Year’s Eve.

    And that’s not to mention the massive uncertainty presented by the specter of future variants. In a briefing Tuesday, Jha acknowledged that “new variant curveballs” could change the government’s plans. But the announcement itself includes no such caveats, which some public-health experts worry could cause problems if course corrections are needed down the line. For all we know, new variants could necessitate more frequent updates, or, if viral mutation slows, we might not even need annual shots, Paul Thomas, an immunologist at St. Jude Children’s Research Hospital, in Tennessee, told me.

    If the routine the White House describes sounds a lot like flu shots, that’s no accident. The announcement explicitly recommends that COVID vaccines be taken between Labor Day and Halloween—“just like your annual flu shot.” That comparison, though, is part of what concerns critics, who worry that the shift into a more flu-like framework will entail the adoption of a vaccines-only approach to COVID prevention. Many of the interventions that have proved so effective over the past two and a half years—masking, distancing, widespread testing—have not traditionally been a major part of our flu-season protocols. If we treat COVID like flu, the thinking goes, such interventions risk falling even further by the wayside. The announcement, which makes no mention of any other prevention tactics, doesn’t offer much reassurance to the contrary.

    But that reading, Jha told me, is “just clearly wrong.” Although vaccines are “the central pillar of our strategy,” he said, testing, masking, and improving indoor air quality are all important as well. But as my colleague Katherine Wu has written, the country has been relying more and more on vaccines—and less and less on the other interventions at our disposal—for some time. Even if you do read the new policy as an abnegation of masking, ventilation, and the like, it may not functionally be much of a departure from the status quo.

    For now, Thomas said, the White House’s plan makes sense—as long as it stays sensitive to changing circumstances. “We keep learning new things about this virus,” he told me. “The rate of mutation is changing. The spread through the population is changing.” And as such, he said, our response must be flexible.

    The White House announcement seems like a good-faith attempt to balance competing priorities: on the one hand, the need to communicate uncertainty and acknowledge complexity; on the other, the need to keep the message from getting so complex that it confuses people to the point that they tune it out entirely. In this case, the administration seems to have come down on the side of simplicity. That could be a mistake, Gellad says—one that public-health authorities have made over and over throughout the pandemic. “When you try and make things simple and understandable and present them without sufficient uncertainty,” he told me, “you get into trouble when things change.”

    [ad_2]

    Jacob Stern

    Source link

  • OptiMed of Kalamazoo Provides COVID Boosters for Ages 12+

    OptiMed of Kalamazoo Provides COVID Boosters for Ages 12+

    [ad_1]

    Press Release


    Jan 6, 2022

    The Center for Disease Control and Prevention (CDC) as of Jan. 5, 2022, recommends COVID-19 boosters for individuals ages 12-17 to maintain immunity longer. COVID-19 boosters help strengthen protection against Omicron and other SARS-CoV-2 variants. 

    “It is critical that we protect our children and teens from COVID-19 infection and the complications of severe disease,” states Dr. Rochelle Walensky, CDC Director.

    “It is critical that we protect our children and teens from COVID-19 infection and the complications of severe disease,” states Dr. Rochelle Walensky, CDC Director. “Today, I endorsed ACIP’s vote to expand eligibility and strengthen our recommendations for booster doses. We now recommend that all adolescents aged 12-17 years should receive a booster shot five months after their primary series. This booster dose will provide optimized protection against COVID-19 and the Omicron variant. I encourage all parents to keep their children up to date with CDC’s COVID-19 vaccine recommendations.” 

    To be eligible for the booster, it must be after five months since the primary series was completed. The primary series is two (2) prior doses of mRNA vaccine (Pfizer or Moderna) – OR – one (1) prior dose of J&J vaccine. Visit vaccines.gov to find a location closest to you or schedule an appointment at OptiMed by clicking here. OptiMed offers clinics every Tuesday and throughout the year.

    About the COVID Clinics: By choosing to vaccinate against COVID-19, you are helping to protect yourself, your family, friends, and the community. OptiMed offers vaccine clinics throughout the year. Visit www.optimedhp.com/covid19-vaccine to learn more about the upcoming clinics offered including First Dose, Second Dose, Third Dose, Boosters, and Doses for Children.

    About OptiMed:  OptiMed Health Partners, headquartered in Kalamazoo, Michigan, is an independently owned and operated national health care organization. For more than 25 years, OptiMed leverages personalized attention to detail to deliver customized solutions that optimize patient outcomes while partnering with other health care organizations to usher in a new standard of excellence. To learn more about OptiMed’s innovative and personalized care, visit www.optimedhp.com.

    Source: OptiMed Health Partners

    [ad_2]

    Source link

  • TS Alliance Advocates for Prioritization of Rare Disease Patients and Caregivers for COVID-19 Vaccines

    TS Alliance Advocates for Prioritization of Rare Disease Patients and Caregivers for COVID-19 Vaccines

    [ad_1]

    Press Release



    updated: Mar 3, 2021

    In partnership with more than 70 advocacy groups, healthcare providers, and biotech companies, the Tuberous Sclerosis Alliance (TS Alliance), an internationally recognized nonprofit that raises awareness and funds to fight the rare genetic disease tuberous sclerosis complex (TSC), recently issued a letter to the National Governors Association that calls on states to immediately prioritize Americans with life-threatening rare diseases in their COVID-19 vaccine rollouts.

    In late January, President Biden announced a strategy committed to vaccine distribution for high-risk individuals, specifically those with underlying conditions, including rare diseases. However, the 25-30 million individuals in the United States with rare diseases and their caregivers have yet to be prioritized in many states. The letter has already been submitted to several states and will be presented to every state in the coming weeks.

    “Due to the complexity of such diseases like TSC, rare disease patients are at an increased high risk for neurological and organ damage if they are infected with COVID-19,” said Kari Rosbeck, President and Chief Executive Officer of the TS Alliance. “Additionally, if their caregivers are exposed and forced to quarantine, it adds additional concerns for irreversible outcomes associated with lack of care and potentially catastrophic consequences for those with rare diseases. This is why prioritizing individuals with rare diseases — as well as their caregivers — in state vaccination plans is an urgent matter.”

    Over the course of the past year, the pandemic has uniquely impacted the rare disease community, in some cases leading to disease regression. Families have lost access to vital resources such as physical, occupational, and speech therapies, and many have also experienced delays in routine care management due to the high risk of exposure to COVID-19 in their communities.

    “This pandemic has highlighted the unique struggles of the rare disease community. We feel we have the responsibility to join forces with nonprofits and advocacy groups to the betterment of the patients we serve,” said Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., one of the letter’s signatories. “As states work through their vaccination rollout plans, we strongly urge them to prioritize rare disease communities because of the unique and heightened risks they face.”

    About TS Alliance

    The TS Alliance is dedicated to finding a cure for tuberous sclerosis complex while improving the lives of those affected. For more information, visit tsalliance.org, call 800-225-6872 or email info@tsalliance.org.

    About Ovid Therapeutics

    Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company is working in rare epilepsies, rare developmental and epileptic encephalopathies. Angelman syndrome, Fragile X syndrome, KIF1A, and other disorders. For more information on Ovid, visit ovidrx.com.

    Co-Signers to the Letter:

    Alagille Syndrome Alliance; Allergy & Asthma Network; Alport Syndrome Foundation; Angelman Syndrome Foundation; Autism Science Foundation; Batten Disease Support and Research Association; Neil S. Belloff, Esq. – Chief Operating Officer and General Counsel, Eloxx Pharmaceuticals, Inc.; BPAN Warriors; Brain Donor Project; Bridge the Gap – SYNGAP Education and Research Foundation; Jeffrey R. Buchhalter, MD; CACNA1A Foundation; Child Neurology Foundation; Wendy Chung, MD, PhD – Kennedy Family Professor of Pediatrics and Medicine, Chief, Clinical Genetics, Columbia University; Coalition to Cure CHD2; COMBINEDBrain; Peter B. Crino, MD, PhD – Chair, Department of Neurology, University of Maryland School of Medicine, Chair, Tuberous Sclerosis Alliance Board of Directors; CURE Epilepsy; CureSHANK; Cute Syndrome Foundation; Cystic Fibrosis Research, Inc.; Danny Did Foundation; Dravet Syndrome Foundation; Dup15q Alliance; Epilepsy Foundation; FamilieSCN2A Foundation; Kyle Fink, PhD – Institute for Regenerative Cures, UC Davis School of Medicine; FOXG1 Research Foundation; Global Genes; Global Liver Institute; Glut1 Deficiency Foundation; GRIN2B Foundation; HCU Network America; Hermansky-Pudlak Syndrome Network; Hope for Hypothalamic Hamartomas; Hope for ULD; IGA Nephropathy Foundation; International Cystinuria Foundation; International Foundation for CDKL5 Research; KCNQ2 Cure Alliance; KIF1A.ORG; Darcy A. Krueger, MD PhD – Clack Endowed Chair in Tuberous Sclerosis, Director, Tuberous Sclerosis Clinic, Professor of Clinical Pediatrics and Neurology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine and Chair, Tuberous Sclerosis Alliance Professional Advisory Board; Patroski Lawson, MSP – CEO, KPM Group DC; Jeremy Levin, DPhil, MB BChir – CEO, Ovid Therapeutics, Chairman, The Biotechnology Innovation Organization; LGS (Lennox-Gastaut Syndrome) Foundation; National Alliance for Caregiving; NORSE Institute; PACS1 Syndrome Research Foundation; PCDH19 Alliance; phaware global association; Phelan-McDermid Syndrome Foundation; Primary Ciliary Dyskinesia Foundation; Project 8p; Pulmonary Fibrosis Foundation; Amit Rakhit, MD, MBA – President and Chief Medical Officer, Ovid Therapeutics; RARE-X; Rare Epilepsy Network (REN); RASopathies Network; Ring14 USA; Mustafa Sahin, MD, PhD – Director, Translational Neuroscience Center, Director, Translational Research Program, Rosamund Stone Zander Chair, Professor of Neurology, Harvard Medical School, Chair, Tuberous Sclerosis Alliance International Scientific Advisory Board; Scleroderma Foundation; Jill Silverman, PhD – MIND Institute, UC Davis School of Medicine; SLC6A1 Connect; SNAP25 Foundation; STXBP1 Foundation; SynGAP Research Fund (SRF); Tbc1d24 Foundation; TESS Research Foundation for SLC13A5 Epilepsy; The Brain Recovery Project: Childhood Epilepsy Surgery Foundation; The Global Foundation for Peroxisomal Disorders; The LAM FoundationThe Schinzel-Giedion Syndrome Foundation; Tuberous Sclerosis Alliance; Wishes for Elliott/DEE-P Connections

    MEDIA CONTACT
    Jaye Isham, jisham@tsalliance.org
    Vice President, Communications Strategy
    Tuberous Sclerosis Alliance

    Source: Tuberous Sclerosis Alliance

    [ad_2]

    Source link